is a medication that belongs to the class of disease-modifying anti-rheumatic drugs (DMARDs). It primarily treats rheumatoid arthritis, a chronic inflammatory condition affecting joints.

Auranofin has been used for several decades as a second-line treatment option for RA. It is typically prescribed when other DMARDs, such as methotrexate or sulfasalazine, have been ineffective or not tolerated. Auranofin is available in oral tablet form, and its exact mechanism of action still needs to be fully understood. However, it is believed to inhibit certain enzymes involved in the inflammatory process.

Auranofin in RA reduces pain, swelling, and stiffness while improving joint function and overall quality of life. It is often combined with other medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids, for better symptom control.

Auranofin, known by its trade name Ridaura, was discovered and developed as a medicinal compound in the late 1970s and early 1980s. The mixture was initially investigated for its potential to prevent destructive cell properties before its applications in rheumatoid arthritis (RA) treatment were discovered.

During their investigations, Cox and Thurman synthesized auranofin, which has a unique organic gold structure. The compound demonstrated impressive anti-disease activity in various preclinical models, showing promise as a potential chemotherapy agent.

However, the scientists noticed another exciting effect of auranofin during their research. In addition to its potential anti-cancer properties, they observed that auranofin also possessed potent anti-inflammatory effects. This led to a shift in focus towards investigating its therapeutic potential for inflammatory conditions, particularly rheumatoid arthritis.

By the early 1980s, clinical trials were conducted to evaluate the efficacy of auranofin in rheumatoid arthritis. The results showed that auranofin effectively reduced joint inflammation, relieved pain, and improved joint function in individuals with RA.

Based on these positive outcomes, auranofin was approved for clinical use in the treatment of rheumatoid arthritis by the FDA in 1985. It became the first oral gold compound to receive approval for RA treatment, providing an alternative for patients unable to tolerate other DMARDs.

In conclusion, auranofin was discovered in the late 1970s as part of research into potential anticancer agents. Its subsequent discovery of anti-inflammatory properties led to its exploration in the treatment of rheumatoid arthritis. After successful clinical trials, the FDA approved auranofin for use in RA treatment in 1985, marking a significant milestone in managing this chronic autoimmune disease.

Another possible mechanism is the impact of auranofin on immune cell function. It is thought to modulate the activity of immune cells, such as T cells and macrophages, which are involved in the inflammatory response seen in RA. Auranofin may affect the production and release of pro-inflammatory cytokines, substances that contribute to inflammation, thereby reducing the overall immune response in RA.
 

E-mail: sales@sonwu.com